Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas

Clinics in Dermatology

Volumn 26, Issue 5, 2008, Pages 448-459

  Wozel, Gottfried ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CLARELUX; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DEFLATOP; DITHRANOL; EFALIZUMAB; ELOSALIC; ETANERCEPT; ETRETIN; FUMARIC ACID; HYDROCORTISONE; INFLIXIMAB; LEFLUNOMIDE; LUXIQ; METHOTREXATE; PLACEBO; PSORADEXAN; PSORALON; SALICYLIC ACID; TACALCITOL; TAZAROTENE; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BURN; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EDEMA; ERYTHEMA; ERYTHEMATOSQUAMOUS SKIN DISEASE; ERYTHRODERMA; HAIR DISCOLORATION; HAIR LOSS; HUMAN; NAIL; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCALP; SIDE EFFECT; SKIN PAIN; STAINING; TREATMENT DURATION;

HUMANS; INTERTRIGO; NAIL DISEASES; PSORIASIS; SCALP DERMATOSES;

EID: 49849094518     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.10.026     Document Type: Article

References (93)

1. Mehlis S.t., and Gordon K.B. From laboratory to clinic: rationale for biologic therapy. In: Menter A., and Cather J. (Eds). Dermatologic clinics-psoriasis (2004), Saunders, Philadelphia 371-377
2. Sterry W., Barker J.N., Boehncke W.H., et al. Biological therapies in the systemic management of psoriasis. Br J Dermatol 151 suppl. (2004) 3-17
3. Rapp S.R., Feldman S.R., Exum M.L., et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
4. van de Kerkhof P.C.M. Clinical features. In: van de Kerkhof P.C.M. (Ed). Textbook of psoriasis. 2nd ed (2003), Blackwell, Oxford 3-29
5. van de Kerkhof P.C.M., and Franssen M.E.J. Psoriasis of the scalp-diagnosis and management. Am J Clin Dermatol 2 (2001) 159-165
6. Farber E.M., and Nall L. Natural history and treatment of scalp psoriasis. Cutis 49 (1992) 396-400
7. van der Vleuten C.J.M., and van de Kerkhof P.C.M. Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs 61 (2001) 1593-1598
8. Schoorl W.J., Baar H.J., and van de Kerkhof P.C.M. The hair root patient in psoriasis of the scalp. Acta Derm Venereol 72 (1992) 141-142
9. Rosenberg E.W., Noah P.W., Skinner Jr. R.B., et al. Microbial associations of 167 patients with psoriasis. Acta Derm Venereol 69 suppl. (1989) 72-75
10. Rosenberg E.W., Noah P.W., and Skinner Jr. R.B. Microorganisms and psoriasis. J Natl Med Assoc 86 (1994) 305-310
11. van de Kerkhof P.C.M., de Hoop D., deKorte J., et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 197 (1998) 326-334
12. Chen S.C., Yeung J., and Chren M.M. Scalpdex. A quality-of-life instrument for scalp dermatitis. Arch Dermatol 138 (2002) 803-807
13. van de Kerkhof PCM, Salonen S-H, on behalf of the EUROPSO Patient Survey Study Group. Large-scale European survey of quality of life in patients with psoriasis: second phase results on quality of life and treatment reported by 7,525 members of European psoriasis patient associations. Published by the European Federation of Psoriasis Foundations (EUROPSO), Helsinki, Finland. Available from: http://www.europso.org/ [Sept. 2006].
14. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 53 suppl. 1 (2005) 59-69
15. Winterfield L.S., Menter A., Gordon K., et al. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 64 suppl. (2005) 87-90
16. Winterfield L.S., and Menter A. Infliximab. Dermatol Ther 17 (2004) 409-426
17. Schaefer H., and Redelmeier T.E. Skin barrier-principles of percutaneous absorption (1996), Karger, Basel 153-212
18. Callis K.P., and Krueger G.G. Topical agents in the treatment of moderate-to-severe psoriasis. In: Weinstein G.D., and Gottlieb A.B. (Eds). Therapy of moderate-to-severe psoriasis. 2nd ed. (2003), Marcel Dekker, New York, Basel 29-51
19. Papp K., Berth-Jones J., Kragballe K., et al. Scalp psoriasis-new treatment options are needed. Poster. 15th Congress of the EADV, October, 4-8 (2006) Rhodos, Greece
20. Mason J., Mason A.R., and Cork M.J. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 146 (2002) 351-364
21. Koo J., Cuffie C.A., Tanner D.J., et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicentre study. Clin Ther 20 (1998) 283-291
22. Galewski E. Über Cignolin, ein Ersatzpräparat des Chrysarobins. Dermatol Wochenschr 62 (1916) 113-115
23. Haas N., Wulff-Woesten A., Sterry W., et al. Dithranol in the treatment of scalp psoriasis. J Dtsch Dermatol Ges 1 (2003) 688-693
24. Schäfer-Korting M., and Gysler A. Topical glucocorticoids with improved benefit/risk ratio. In: Korting H.C., and Schäfer-Korting M. (Eds). The benefit/risk ratio: a handbook for the rational use of potentially hazardous drugs (1999), CRC Press, Boca Raton 359-372
25. Cornell R.C., and Stoughton R.B. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 121 (1985) 63-67
26. Niedner R., and Ziegenmeyer J. Dermatika-Therapeutischer Einsatz, Pharmakologie und Pharmazie (1992), Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 76-88
27. Roeder A., Schaller M., Schafer-Korting M., et al. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol 18 (2005) 3-11
28. Wozel G. Is the psoriasis plaque test still relevant in the age of biologicals?. Hautarzt 57 (2006) 672-678
29. van de Kerkhof P.C.M., and Vissers W.H.P.M. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 16 (2003) 69-83
30. Pauporte M., Maibach H., Lowe N., et al. Fluocinolone acetonide topical oil or scalp psoriasis. J Dermatol Treat 15 (2004) 360-364
31. Olsen E.A., Cram D.L., Ellis C.N., et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 24 (1991) 443-447
32. Franz T.J., Parsell D.A., Halualani R.M., et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 38 (1999) 628-632
33. Melian E.B., Spencer C.M., and Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol 2 (2001) 89-93
34. Andreassi L., Giannetti A., Milani M., and Scale investigators Group. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 148 (2003) 134-138
35. Gottlieb A.B., Ford R.O., and Spellman M.C. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 7 (2003) 185-192
36. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol 53 suppl. (2005) 39-49
37. 14C cortisol in man. J Invest Dermatol 48 (1967) 181-183
38. Morimoto S., Yoshikawa K., Kozuka T., et al. An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 115 (1986) 421-429
39. Fogh K., and Kragballe K. New vitamin D analogs in psoriasis. Curr Drug Targets Inflamm Allergy 3 (2004) 99-204
40. van de Kerkhof P.C.M., and Kragballe K. Recommendations for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 19 (2005) 495-499
41. Kragballe K. Calcipotriol: a new drug for topical psoriasis treatment. Pharmacol Toxicol 77 (1995) 241-246
42. Scott L.J., Dunn C.J., and Goa K.L. Calcipotriol ointment: a review of its use in the management of psoriasis. Am J Clin Dermatol 2 (2001) 95-120
43. Workshop on topical treatment options in psoriasis vulgaris. Meeting of the Copenhagen Psoriasis Working group. December, 12-13 (2003) Copenhagen, Denmark
44. Thaci D., Daiber W., Boehncke W.H., et al. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 203 (2001) 153-156
45. Duweb G.A., Abuzariba O., Rahim M., et al. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J Clin Pharmacol Res 20 (2000) 65-68
46. Green C., Ganpule M., Harris D., et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol 130 (1994) 483-487
47. Barnes L., Altmeyer P., Forstrom L., et al. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 10 (2000) 199-204
48. Buckley C., and Hoffmann V. Calcipotriol plus betamethasone dipropionate gel (LEO80185) is effective and safe in the treatment of scalp psoriasis (a phase II study). J Eur Acad Dermatol Venereol 19 suppl. 2 (2005) 175
49. Farber E.M., and Nall L. Nail psoriasis. Cutis 50 (1992) 174-178
50. van Laborde S., and Scher R.K. Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis. Dermatol Clin 18 (2000) 37-46
51. de Jong E.M.G.J., Seegers B.A.M.P.A., Gulinck M.K., et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 193 (1996) 300-303
52. Rich P., and Scher R.K. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 49 (2003) 206-212
53. de Berker D. Management of nail psoriasis. Clin Exp Dermatol 25 (2000) 357-362
54. Bianchi L., Soda R., Diluvio L., et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 149 (2003) 207-209
55. Rigopoulos D., Ioannides D., Prastitis N., et al. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 82 (2002) 140
56. Scher R.K., Stiller M., and Zhu Y.I. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 68 (2001) 355-358
57. Tosti A., Piraccini B.M., Cameli N., et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 139 (1998) 655-659
58. Zakeri M., Valikhani M., Mortazavi H., et al. Topical calcipotriol therapy in nail psoriasis: a study of 24 cases. Dermatol J Onlin 11 (2005) 5
59. deJong E.M., Menke H.E., van Praag M.C., et al. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 199 (1999) 313-318
60. Frederiksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol 110 (1974) 735
61. Schissel D.J., and Elston D.M. Topical 5-fluourouracil treatment for psoriatic trachyonychia. Cutis 62 (1998) 27-28
62. Cannavo S.P., Guarneri F., Vaccaro M., et al. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 206 (2003) 153-156
63. Feliciani C., Zampetti A., Forleo P., et al. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg 8 (2004) 122-125
64. Yamamoto T., Katayama I., and Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 25 (1998) 231-233
65. Arnold W.P., Gerritsen M.J., and van de Kerkhof P.C.M. Response of nail psoriasis to cyclosporin. Br J Dermatol 129 (1993) 750-751
66. Mahrle G., Schulze H.J., Färber L., et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 32 (1995) 78-88
67. Baran R. Retinoids and the nails. J Dermatol Treat 1 (1990) 151-159
68. Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
69. Parrish C.A., Sobera J.O., Robbins C.M., et al. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 5 (2006) 339-340
70. Rich P., Gupta A., Wang A., et al. Etanercept improves nail psoriasis. J Am Acad Dermatol 52 suppl. 3 (2005) 184
71. Sobera J., Parrish C., and Elewski B. Improvement in nail psoriasis with alefacept. J Am Acad Dermatol 50 suppl. 3 (2004) 145
72. Flytstroem I., Bergbrant I.M., Braared J., et al. Microorganisms in intertriginous psoriasis: no evidence of Candida. Acta Derm Venereol 83 (2003) 121-123
73. Vissers W.H.P.M., Roelofzen J., DeJong E.M.G.J., et al. Flexural versus plaque lesions in psoriasis: an immunohistochemical differentiation. Eur J Dermatol 15 (2005) 3-17
74. Barardesca E., and Maibach H.I. Skin occlusion: treatment or drug-like device?. Skin Pharmacol 1 (1988) 207-215
75. Thaci D., Paetzold S., and Kaufmann R. Treatment of intertriginous and genito-anal psoriasis. Akt Dermatol 29 (2003) 505-508
76. Lebwohl M.G., Tan M.H., Meador S.L., et al. Limited application of fluticasone propionate ointment, 0,005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 44 (2001) 77-82
77. Kreuter A., Sommer A., Hyun J., et al. 1% Pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 142 (2006) 1138-1143
78. Duweb G.A., Eldebani S., and Alhaddar J. Calcipotriol cream in the treatment of flexural psoriasis. Int J Tissue React 25 (2003) 127-130
79. Kienbaum S., Diercks K., Lehmann P., et al. Calcipotriol in the treatment of intertriginous psoriasis. Zeitschr Hautkr 70 (1995) 764-766
80. Schlehaider U.K., and Kowalzick L. Cream based calcipotriol for the treatment of inverse psoriasis and seborrheic dermatitis. Akt Dermatol 22 (1996) 345-348
81. Travis L.B., and Silverberg N.B. Psoriasis in infancy. Therapy with calcipotriene ointment. Cutis 68 (2001) 341-344
82. -1 ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 148 (2003) 326-333
83. Kienbaum S., Lehmann P., and Ruzicka T. Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol 135 (1996) 647-650
84. Langner A., Stapor V., Verjans H., et al. Calcitriol ointment in the treatment of facial, hairline and retroauricular chronic plaque psoriasis. J Dermatol Treat 7 suppl. (1996) 15-18
85. Gang W., Chunying L., Tianwen G., et al. Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study. Eur J Dermatol 15 (2005) 176-178
86. Reitamo S., Rissanen J., Remitz A., et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 111 (1998) 396-398
87. Freeman A.K., Linowski G.J., Brady C.h., et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 48 (2003) 564-568
88. Kleyn C.E., Woodcock D., and Sharpe G.R. The efficacy of 0,1% tacrolimus ointment compared with clobetasonebutyrate 0,05% ointment in patients with facial, flexural or genital psoriasis. Br J Dermatol 153 (2005) p33
89. Lebwohl M.G., Freeman A.K., Chapman M.S., et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51 (2004) 723-730
90. Martin Ezquerra G., Sanchez Regana M., Herrera Acosta E., et al. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 5 (2006) 334-336
91. Steele J.A., Choi C., and Kwong P.C. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 53 (2005) 713-716
92. Wohlrab J. Calcineurin inhibitors for topical therapy in psoriasis. Hautarzt 57 (2006) 685-689
93. Gribetz C., Ling M., Lebwohl M., et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 51 (2004) 731-738